Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Blood

• Publication date

  2014-09-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2014-04-571232PMID 24963045
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

  2014cited by this paper
• Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.

  2014cited by this paper
• Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

  2014influential reference
• Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta‐analysis

  2014cited by this paper
• Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

  2013cited by this paper
• Oral apixaban for the treatment of acute venous thromboembolism.

  2013cited by this paper
• Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin

  2013cited by this paper
• [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism].

  2013cited by this paper
• Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials

  2012cited by this paper
• Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

  2012cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2011cited by this paper
• Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients

  2010cited by this paper
• Oral rivaroxaban for symptomatic venous thromboembolism.

  2010cited by this paper
• Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

  2009cited by this paper
• Effect of study setting on anticoagulation control: a systematic review and metaregression.

  2006cited by this paper
• Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.

  2006cited by this paper
• Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients

  2005cited by this paper

• Economic evaluation of direct oral anticoagulants (DOACs) for venous thromboembolism with different etiologies: a systematic review.

  2026cites this paper
• A systematic review of anticoagulants evaluating efficacy and safety in thromboembolic disease

  2026cites this paper
• Efficacy and Safety of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

  2026cites this paper
• Factors Associated and Survival Outcomes Among Japanese Patients with Solid Cancer Who Developed Deep Vein Thrombosis (DVT)

  2026cites this paper
• Defining significant acute traumatic intracranial injuries in adult patients with traumatic brain injury: a narrative review.

  2026cites this paper
• 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2026cites this paper
• Acute Pulmonary Embolism

  2026cites this paper
• 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

  2026cites this paper
• Anticoagulation in chronic thromboembolic pulmonary hypertension: an updated systematic review and meta-analysis.

  2026cites this paper
• Misdiagnosis of rivaroxaban-associated multiple intracranial hemorrhages as intracranial metastatic tumor: a case report.

  2026cites this paper
• Edoxaban for acute and long-term treatment of venous thromboembolism: real-life data from a single-center cohort study.

  2025cites this paper
• Diagnóstico y tratamiento de la embolia pulmonar. Recomendaciones del Grupo de Enfermedad Tromboembólica de la Sociedad Española de Medicina Interna 2024

  2025cites this paper
• Impact of Anemia Management on Bleeding Outcomes in Anticoagulated Patients: A Retrospective Cohort Analysis

  2025cites this paper
• Silent yet severe: inferior vena cava thrombosis associated with platypnoea–orthodeoxia. Is uterine sarcoma the culprit?

  2025cites this paper
• Reduced-dose vs full-dose direct oral anticoagulants for extended treatment of venous thromboembolism: a meta-analysis of randomized controlled trials

  2025cites this paper
• Submassive and Massive Pulmonary Embolism: An Updated Review of Definition, Diagnosis, and Treatment Strategies.

  2025cites this paper
• Angiologie in der Rhythmologie: Was muss ich über die Gefäßkomplikationen wissen?

  2025cites this paper
• The Use of Direct Oral Anticoagulants (DOACs) in the Geriatric Population—How to Overcome the Challenges of Geriatric Syndromes

  2025cites this paper
• Anticoagulation for extended venous thromboembolism treatment: less is really more.

  2025cites this paper
• Edoxaban for prevention of catheter-related thrombosis in cancer patients: a randomized, multicenter, open-label, control, clinical trail

  2025cites this paper
• Efficacy and safety of anticoagulants in elderly atrial fibrillation patients: a systematic review and network meta-analysis

  2025cites this paper
• Direct Oral Anticoagulants versus Standard Therapy in Upper Extremity Deep Vein Thrombosis: Real-World Evidence

  2025cites this paper
• Enfermedad venosa aguda

  2025cites this paper
• Manejo avanzado de las complicaciones tromboembólicas en los pacientes con tumores sólidos y hematológicos

  2025cites this paper
• Contact phase inhibitors: the future of anticoagulation?

  2025cites this paper
• Direct Oral Anticoagulants for the Treatment of Unusual-Site Venous Thrombosis: An Update

  2025cites this paper
• Efficacy and safety of anti-Xa direct oral anticoagulants vs. warfarin in patients homozygous for Factor V Leiden and prothrombin G20210A mutations

  2025cites this paper
• Hematologic Complications of Pregnancy

  2025cites this paper
• Diagnostik und Therapie der akuten Lungenembolie

  2025cites this paper
• No shots needed: direct oral anticoagulants in cancer-associated thrombosis-10-year follow-up.

  2025cites this paper
• New horizons in the pharmacological management of venous thromboembolism

  2025cites this paper
• Apixaban vs. vitamin K antagonists in relation to the post-thrombotic syndrome; data from a prospective cohort study.

  2025cites this paper
• Carbon footprint of direct oral anticoagulants in atrial fibrillation and venous thromboembolism.

  2025cites this paper
• Modernising Acute PE and VTE Management: Meta-Analysis of Newer Anticoagulants Versus Traditional Therapy on Recurrence and Mortality.

  2025cites this paper
• Transitioning of Patients from Direct-Acting Oral Anticoagulant to Heparin: Impact on Laboratory Testing

  2025cites this paper
• Measuring Direct Oral Anticoagulant Levels in Laboratory Practice: Impact of Different Storage Conditions of Blood Samples

  2025cites this paper
• Quelle place reste-t-il pour les antivitamines K ?

  2025cites this paper
• Risk Factors Associated with Thrombus Development Following Pharmacologic Anticoagulation Reversal with Coagulation Factor Xa [Recombinant], Inactivated-zhzo.

  2025cites this paper
• How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: Communication from the ISTH SSC Subcommittee on Control of Anticoagulation.

  2025cites this paper
• [Diagnosis and treatment of acute pulmonary embolism].

  2025cites this paper
• Diagnosis and treatment of pulmonary embolism. Recommendations of the Thromboembolic Disease Group of the Spanish Society of Internal Medicine 2024.

  2025cites this paper
• Development of new anticoagulants targeting coagulation factor XI and prospects for clinical use.

  2025cites this paper
• Manual to Auto-Optimization Platform of Multistep Apixaban Synthesis

  2025cites this paper
• Percutaneous Patent Foramen Ovale Occlusion in Patients Over 60 Years of Age with History of Stroke

  2025cites this paper
• Anticoagulation Therapy for Venous Thromboembolism.

  2025cites this paper
• The critical role of platelets in venous thromboembolism: Pathogenesis, clinical status, and emerging therapeutic strategies.

  2025cites this paper
• Comparison of direct oral anticoagulants and vitamin K antagonists in the treatment of left ventricular thrombi: a retrospective cohort study

  2025cites this paper
• Pharmacists’ Knowledge of Abnormal Uterine Bleeding in Women on Anticoagulant Therapy: A French Survey

  2025cites this paper
• Effectiveness and safety of rivaroxaban vs warfarin in patients with pulmonary embolism and right ventricular dysfunction: a retrospective cohort study

  2025cites this paper
• Emerging trends in anticoagulation therapy: a bibliometric analysis of DOACs and endogenous coagulation pathway inhibitors

  2025cites this paper
• Older patients with pulmonary embolism: a state-of-the-art review

  2025cites this paper
• [Diagnosis and treatment of acute pulmonary embolism].

  2025cites this paper
• A closer look at gender disparities in patients with pulmonary embolism

  2025cites this paper
• Safety and effectiveness of direct oral anticoagulants in fragile patients with venous thromboembolism: a retrospective cohort observational study

  2025cites this paper
• Prediction Score for Major Bleeding in Patients With Venous Thromboembolism Receiving Direct Oral Anticoagulants　- Insights From the COMMAND VTE Registry-2.

  2025cites this paper
• Characterizing Anticoagulation Reversal Practices in Colombia: Initial Insights from a National Registry

  2025cites this paper
• Unmet Needs and Future Direction for Pulmonary Embolism Interventions.

  2025cites this paper
• Anticoagulants: From chance discovery to structure-based design.

  2025cites this paper
• The Aftermath of Pulmonary Embolism: Are Residual Thrombi Clinically Significant?

  2025cites this paper
• Bleeding risk on rivaroxaban versus apixaban in older patients with venous thromboembolism: a nationwide observational register-based study.

  2025cites this paper
• Anticoagulation for cancer-associated venous thromboembolism: navigating between risks of recurrence and bleeding.

  2025cites this paper
• Advances in Transdermal Drug Delivery Systems for Antithrombotic Therapy: A Systematic Review.

  2025cites this paper
• 2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri‐operative and bleeding management

  2025cites this paper
• Current practices and challenges in the management of cancer-associated thrombosis: a survey of Italian oncologists

  2025cites this paper
• Low-dose of direct oral anticoagulants for secondary prevention in patients at high risk for recurrence due to history of recurrent venous thromboembolic events or to severe thrombophilia: a retrospective analysis of the Italian START2 Registry.

  2025cites this paper
• Machine Learning in Venous Thromboembolism—Why and What Next?

  2025cites this paper
• Three Year Follow-Up of Reduced Dose of Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: An Ambispective Cohort Study

  2025cites this paper
• Optimizing Perioperative Anticoagulant Management: Balancing Thromboembolic and Bleeding Risks.

  2025cites this paper
• Usefulness and Limits of DOAC Removal Agents Based on Activated Charcoal in Thrombophilia Testing: Literature Review and Expert Proposals

  2025cites this paper
• Clinical Practice Recommendations for the Management of Lower Limb Deep Vein Thrombosis in India

  2025cites this paper
• Temporal Changes in Long‐Term Outcomes of Venous Thromboembolism From the Warfarin Era to the Direct Oral Anticoagulant Era

  2024cites this paper
• Anticoagulant therapy today: from DOACS to factor XI inhibitors

  2024cites this paper
• Current Antithrombotic Treatments for Cardiovascular Diseases: A Comprehensive Review

  2024cites this paper
• “What Keeps Me up at Night”: Complications in Foot and Ankle Surgery

  2024cites this paper
• Exploring the therapeutic utility of the factor XIa inhibitor asundexian.

  2024cites this paper
• Anticoagulation and compression therapy for proximal acute deep vein thrombosis.

  2024cites this paper
• Preventative and curative treatment of venous thromboembolic disease in cancer patients.

  2024cites this paper
• Efficacy and safety of rivaroxaban versus warfarin in the management of unusual site deep vein thrombosis: a retrospective cohort study

  2024cites this paper
• Rivaroxaban for stroke patients with antiphospholipid syndrome (RISAPS): protocol for a randomized controlled, phase IIb proof-of-principle trial

  2024cites this paper
• Cerebral Vein Thrombosis and Direct Oral Anticoagulants: A Review

  2024influential citation
• Comparison of patency rates and complications with or without antithrombotic therapy following portal vein stent placement after pancreatic surgery: a systematic review and meta-analysis

  2024cites this paper
• Cerebral venous sinus thrombosis associated with cancer: analysis of the ACTION-CVT study

  2024cites this paper
• Pulmonary embolism in cancer patients. Effectiveness of vitamin K antagonists and direct oral anticoagulants in long-term therapy

  2024cites this paper
• Persistent Peril: Recurrent Deep Vein Thrombosis and Pulmonary Embolism in a Patient With Protein S Deficiency Despite Optimal Anticoagulation Therapies

  2024influential citation
• Evaluation of the safety and efficacy of direct oral anticoagulants compared with vitamin-k antagonists in the treatment of left ventricular thrombosis. A systematic review and meta-analysis.

  2024cites this paper
• Bleeding Outcomes of Direct Oral Anticoagulants and Vitamin K Antagonists for Acute Venous Thromboembolism: A Cross-Sectional Study

  2024cites this paper
• Engineering and evaluation of FXa bypassing agents that restore hemostasis following Apixaban associated bleeding

  2024cites this paper
• How We Interpret Thrombosis with Thrombocytopenia Syndrome?

  2024cites this paper
• Warfarin intake in relation to diagnosis reduces mortality in patients with colorectal cancer - a register-based study.

  2024cites this paper
• Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings

  2024cites this paper
• Reversal and resumption of anticoagulants in patients with anticoagulant-associated intracerebral hemorrhage

  2024cites this paper
• Is there a role for the laboratory monitoring in the management of specific antidotes of direct oral anticoagulants?

  2024cites this paper
• Oral anticoagulant therapy in older adults.

  2024cites this paper
• Outcomes of direct oral anticoagulants with aspirin vs warfarin with aspirin: a registry-based cohort study

  2024cites this paper
• Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis

  2024cites this paper
• Dual direct oral anticoagulant therapy in challenging thrombosis: a case series

  2024cites this paper
• Clinical Practice Guideline for detection and management of diabetic kidney disease: A consensus report by the Spanish Society of Nephrology.

  2024cites this paper
• Significance of bleeding during acute pulmonary thromboembolism treatment

  2024cites this paper
• Anemia and Prognosis in Patients with Acute Venous Thromboembolism

  2024influential citation
• Pre-Operative Direct Oral Anticoagulant Level Measurement Reduces Time to Surgery in Hip Fracture Patients

  2024cites this paper